Workenhe Samuel T, Verschoor Meghan L, Mossman Karen L
Department of Pathology & Molecular Medicine, McMaster Immunology Research Centre, Institute for Infectious Disease Research, McMaster University, Hamilton, Ontario, Canada.
Future Oncol. 2015;11(4):675-89. doi: 10.2217/fon.14.254.
ABSTRACT Despite huge economic and intellectual investments, developing effective cancer treatments continues to be an overarching challenge. Engineered oncolytic viruses (OVs) present self-amplifying immunotherapy platforms capable of preferential cytotoxicity to cancer cells and simultaneous activation of host anti-tumor immunity. In preclinical studies, OVs are showing potent therapeutic effects when used in combination with other immune therapy strategies. In the clinic, the immunotherapeutic effects of OVs are showing promising results. Here we review current strategies for engineering OVs, and present a perspective of future directions within a discussion of the current outcomes of combinatorial approaches with other cancer immunotherapy platforms.
摘要 尽管投入了巨大的经济和智力资源，但开发有效的癌症治疗方法仍然是一项首要挑战。工程化溶瘤病毒（OVs）提供了自我扩增的免疫治疗平台，能够对癌细胞产生优先的细胞毒性，并同时激活宿主抗肿瘤免疫。在临床前研究中，OVs与其他免疫治疗策略联合使用时显示出强大的治疗效果。在临床上，OVs的免疫治疗效果也显示出令人鼓舞的结果。在此，我们综述了工程化OVs的当前策略，并在讨论与其他癌症免疫治疗平台联合应用的当前成果的背景下，展望未来的发展方向。
